Dose adjustment may be needed in patients with kidney disease, please consult your doctor
Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA)
blending in a Turbula mixer (WAB, Muttenz, Switzerland)
The primary endpoint was major adverse cardiovascular events (often called MACE), a combined measure of: Cardiovascular death Nonfatal heart attack Nonfatal stroke Over a median follow-up of about 3.5 years, semaglutide reduced the relative risk of these events by about 20% compared with placebo
Antipsychotic drug and body weight set-point
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with with type 2 diabetes mellitus who are at high risk for these events